Named Q1 Scientific, the service offers environmentally-controlled stability storage services to the pharmaceutical, medical device and life sciences industries
US-based contract development manufacturing organisation (CDMO) Cambrex has announced the expansion of its stability storage business.
Named Q1 Scientific, the service offers environmentally-controlled stability storage services to the pharmaceutical, medical device and life sciences industries. Q1 Scientific will open a new 20,000 sqft cGMP facility in Belgium and add an additional 10,000 square feet at their existing facility in Waterford, Ireland. The expansions will be completed in the first half of 2023.
Q1 Scientific's new state-of-the-art temperature-controlled and monitored storage facility in Belgium will be located in the easily accessible Liege region, approximately 50 miles from Brussels. The facility will provide 35,000 temperature-controlled storage spaces for all key ICH climatic zones, supporting long-term, intermediate and accelerated stability trials, including 2 – 8°C and 25°C / 60%RH and 40°C / 75%RH.
Operating two sites will be a great benefit to our European customers, who can now expect even faster turnaround times for the return of samples
Tom Loewald, CEO at Cambrex, said: "We are delighted to expand the Q1 Scientific business into Belgium, where we will be able to serve pharmaceutical companies across Germany, France, and the Netherlands. Simultaneously, we will continue to expand our Waterford facility to meet the demand within the Irish market."
Q1 Scientific's Waterford-based facility has doubled in size over the past two years and continues to grow with this new 10,000 sqft expansion.
"With Cambrex's scientific expertise and scale, we are able to accelerate our growth plans and launch a second site in 2023," added Stephen Delaney, Managing Director of Q1 Scientific. "Operating two sites will be a great benefit to our European customers, who can now expect even faster turnaround times for the return of samples. Meanwhile, we will also be able to provide greater temperature-controlled transport options in mainland Europe."
Cambrex continues to expand its capabilities and capacity across its North American and European network to meet the growing demand for outsourced drug development and manufacturing services.